Eli Lilly expects its combination with ImClone to deliver $15.5 billion in revenues for the nine months ended Sept. 30 and a combined EPS of 1.21, which because of acquisition costs and interest expenses is some 20 cents per share less than Lilly would have produced on its own. Report
Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product
Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.